CBD Prevented Colorectal Precancerous Growths by Suppressing Immune-Blocking Cells

CBD prevented colorectal adenomas in both AOM/DSS and high-fat diet Apcmin/+ mouse models by binding to EEF1B2, inhibiting C/EBPb protein synthesis, and suppressing MDSC generation. This restored T-cell activation against developing tumors.

Two established colorectal adenoma mouse models were used. Single-cell RNA sequencing identified immune environment changes. Target-responsive accessibility profiling identified EEF1B2 as CBD's binding target. Multiple immunology and molecular biology experiments confirmed the mechanism.

Colorectal cancer develops from adenomas over years, making early intervention critical. This study identifies a specific molecular mechanism by which CBD could prevent precancerous growths through immune system modulation, not direct tumor cell killing.

MDSCs are a major obstacle to cancer immunotherapy across many tumor types. If CBD can suppress MDSC generation at the adenoma stage, it could potentially complement existing cancer prevention strategies, though this remains far from proven in humans.

Mouse models only. The specific doses and routes of CBD administration in mice may not translate to achievable human concentrations. The Apcmin/+ model has a specific genetic mutation not present in all human colorectal cancers.